Market for ureteral stent can be analyzed by estimating market for each of Ureteral Stent’s fundamental use. Other uses of Ureteral Stent include Post-surgical swelling/infection of uterus, Active kidney infection etc.
=='''Kidney Stones Market'''==
There are four main types of treatments available for curing kidney stones based on type of Kidney Stone, listed as follows
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Sr. No.'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Treatment'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Indications'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Requirement of Ureteral Stent'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''% of cases in general'''</font>
|-
|align = "right" bgcolor = "#DBE5F1"|1
|bgcolor = "#DBE5F1"|Lithotripsy
|bgcolor = "#DBE5F1"|Radiolucent calculi, Renal stones <nowiki><</nowiki>2 cm, Ureteral stones <nowiki><</nowiki>1 cm
|bgcolor = "#DBE5F1"|No
|align = "right" bgcolor = "#DBE5F1"|49.07%<nowiki>*</nowiki>
|-
|align = "right"|2
|Ureteroscopy
|Ureteral stones
|Yes
|align = "right"|15.48%<nowiki>*</nowiki>
|-
|align = "right" bgcolor = "#DBE5F1"|3
|bgcolor = "#DBE5F1"|Ureterorenoscopy
|bgcolor = "#DBE5F1"|Renal stones <nowiki><</nowiki>2 cm
|bgcolor = "#DBE5F1"|Yes
|align = "right" bgcolor = "#DBE5F1"|0.47%<nowiki>*</nowiki>
|-
|align = "right"|4
|Percutaneous nephrolithotomy
|Renal stones <nowiki>></nowiki>2 cm, Proximal ureteral stones <nowiki>></nowiki>1 cm
|No
|align = "right"|34.98%<nowiki>*</nowiki>
|-
|}
<nowiki>*</nowiki>Dolcera Estimate 2011
As seen in table ureteral stent is required for Ureteroscopy and Ureterorenoscopy which together constitute for around 16% of Kidney stone cases.
Total Number of Kidney Stone Cases in US in 2006: 166,000
Approximate Stents required in 2006 = 166,000<nowiki>*</nowiki>0.16=26560
=='''Kidney Transplant Market'''==
Every kidney transplant operation required ureteral stent to be placed in Patient<nowiki>’</nowiki>s body for few days till newly placed kidney adapts to Patients<nowiki>’</nowiki> body
Total No. of Kidney Transplants done in United States in 2007 are approx. 17,513
Total Market for Ureteral Stents in 2007 is 17,513
{|border="2" cellspacing="0" cellpadding="4" width="54%"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Year'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''No. of Kidney Transplants'''</font>
|-
|align = "right"|'''2007'''
| 17,513
|-
|align = "right"|'''2006'''
| 18,056
|-
|align = "right"|'''2005'''
| 17,443
|-
|align = "right"|'''2000'''
| 14,611
|-
|align = "right"|'''1995'''
| 12,160
|-
|align = "right"|'''1990'''
| 10,029
|-
|align = "right"|'''1985'''
| 7,504
|-
|align = "right"|'''1980'''
| 3,785
|-
|}
=='''Urinary Incontinence Market'''==
'''Inpatient hospital stays:'''The estimated number of hospital admissions among adults ages 18 or older with urinary incontinence listed as a diagnosis: <br>'''(2000):''' 47,802 hospital stays (1,332 men; 46,470 women)
{|border="2" cellspacing="0" cellpadding="4" width="40%"
|align = "center" bgcolor = "#5CB3FF" colspan = "2"|'''Prevalence of Urinary Incontinece in US (Women)'''
|-
|bgcolor = "#5CB3FF"|'''Age (in years)'''
|'''Population with Urinary Incontinence (in %)'''
|-
|bgcolor = "#5CB3FF"|30-39
|align = "center"|28
|-
|bgcolor = "#5CB3FF"|40-49
|align = "center"|41
|-
|bgcolor = "#5CB3FF"|50-59
|align = "center"|48
|-
|bgcolor = "#5CB3FF"|60-69
|align = "center"|51
|-
|bgcolor = "#5CB3FF"|70-79
|align = "center"|55
|-
|bgcolor = "#5CB3FF"|≥ 80
|align = "center"|54
|-
|}
{|border="2" cellspacing="0" cellpadding="4" width="102%"
|align = "center" colspan = "6"|'''Estimated cases for ureteral stents in US, 2010'''
|-
|bgcolor = "#5CB3FF"|Age groups
|bgcolor = "#5CB3FF"|A) Female population (Million)
|bgcolor = "#5CB3FF"|B) Prevalence rate in female (%)
|bgcolor = "#5CB3FF"|C=A<nowiki>*</nowiki>B Affected population<br>(Million)
|bgcolor = "#5CB3FF"|D) Catherization rate (%)
|bgcolor = "#5CB3FF"|E=C<nowiki>*</nowiki>D<br>Stent market based on catherization
|-
|bgcolor = "#5CB3FF"|30-39
|align = "right"|20.10
|align = "right"|28
|align = "right"|5.62
|align = "right"|0.043
|2420.42
|-
|bgcolor = "#5CB3FF"|40-49
|align = "right"|21.99
|align = "right"|41
|align = "right"|9.01
|align = "right"|0.123
|11092.83
|-
|bgcolor = "#5CB3FF"|50-59
|align = "right"|21.50
|align = "right"|48
|align = "right"|10.32
|align = "right"|0.124
|12800.37
|-
|bgcolor = "#5CB3FF"|60-69
|align = "right"|15.32
|align = "right"|51
|align = "right"|7.81
|align = "right"|0.160
|12503.68
|-
|bgcolor = "#5CB3FF"|70-79
|align = "right"|9.16
|align = "right"|55
|align = "right"|5.04
|align = "right"|0.172
|8674.44
|-
|bgcolor = "#5CB3FF"|≥ 80
|align = "right"|7.15
|align = "right"|54
|align = "right"|3.86
|align = "right"|0.044
|1699.48
|-
|bgcolor = "#5CB3FF"|Total
|align = "right"|95.25
|
|align = "right"|41.69
|
|
|-
|}
* '''Catherization rate''' depicts the actual number of people going in for ureteral stents.
* Prevalence rate in US women is growing at a CAGR of 1.26%
Assuming that each admission in hospital required one ureteral stent, market from Urinary Incontinence is around 47,802 stents per year
'''Total Market for Ureteral Stent'''
Following table displays approximate stent market per year
{|border="2" cellspacing="0" cellpadding="4" width="64%"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Category'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''No. of Stents Required'''</font>
|-
|bgcolor = "#DBE5F1"|Stent Market for Kidney Stones
|align = "center" bgcolor = "#DBE5F1"|26560
|-
|Stent Market for Kidney Transplant
|align = "center"|17513
|-
|bgcolor = "#DBE5F1"|Stent Market for Urinary Incontinence
|align = "center" bgcolor = "#DBE5F1"|47802
|-
|bgcolor = "#4F81BD"|<font color="#FFFFFF">Total</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">91875</font>
|-
|}
* Ureteral stent market is growing at a CAGR of 1.58%
'''[[more on market overview...]]'''
